Last reviewed · How we verify
SAR408701
SAR408701 is a bispecific antibody that simultaneously engages CD40 on antigen-presenting cells and 4-1BB on T cells to enhance anti-tumor immune responses.
SAR408701 is a bispecific antibody that simultaneously engages CD40 on antigen-presenting cells and 4-1BB on T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | SAR408701 |
|---|---|
| Also known as | Tusamitamab ravtansine |
| Sponsor | Sanofi |
| Drug class | Bispecific antibody; CD40/4-1BB agonist |
| Target | CD40 and 4-1BB (TNFRSF9) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By cross-linking CD40 and 4-1BB, SAR408701 activates dendritic cells and co-stimulates T cell proliferation and effector function. This dual engagement amplifies both innate and adaptive immune responses against cancer cells, potentially overcoming tumor immune evasion mechanisms.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Cytokine release syndrome
- Fatigue
- Infusion-related reactions
- Elevated liver enzymes
Key clinical trials
- Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (PHASE2)
- Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors (PHASE2)
- Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (PHASE2)
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (PHASE2)
- SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (PHASE3)
- Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors (PHASE1)
- Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (PHASE2)
- Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |